Skip to main content

View full-text article in PMC

. 2022 Nov 1;12(10):146. doi: 10.1038/s41408-022-00741-2

Table 7.

Maximum CRS and ICANS in multiple myeloma cohort.

	Early G-CSF* (N = 24)	Control^a (N = 23)	Overall (N = 47)
CRS grade^b
0	4 (16.7%)	3 (13.0%)	7 (14.9%)
1	12 (50.0%)	11 (47.8%)	23 (48.9%)
2	8 (33.3%)	8 (34.8%)	16 (34.0%)
3	0 (0%)	1 (4.3%)	1 (2.1%)
ICANS grade^b
0	21 (87.5%)	18 (78.3%)	39 (83.0%)
1	1 (4.2%)	3 (13.0%)	4 (8.5%)
2	1 (4.2%)	0 (0%)	1 (2.1%)
3	0 (0%)	2 (8.7%)	2 (4.3%)
4	1 (4.2%)	0 (0%)	1 (2.1%)

^*Early G-CSF group received G-CSF within ≤2 days after CAR T.

^aControl group either received G-CSF ≥ 3 days after CAR T (N = 21) or were not exposed to G-CSF (N = 2).

^bMaximum CRS/ICANS grade per ASTCT consensus criteria.